Study of People With Rheumatoid Arthritis Who Require Joint Surgery in the Hand
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00124254|
Recruitment Status : Completed
First Posted : July 27, 2005
Last Update Posted : August 22, 2017
|Condition or disease||Intervention/treatment||Phase|
|Arthritis, Rheumatoid||Procedure: Silicone metacarpophalangeal joint arthroplasty Other: Usual care||Not Applicable|
The purpose of this study is to provide a better understanding of the effectiveness of SMPA, a procedure to correct knuckle deformity in the hands of rheumatoid arthritis patients. This study will examine whether rheumatoid arthritis patients who undergo SMPA will have better outcomes than those patients who do not have this surgery.
RA affects 2.1 million Americans and costs the United States an estimated $8.7 billion annually in medical costs and wages. RA is a progressive disease, and approximately 25% of RA patients experience hand deformities associated with the destruction of the metacarpophalangeal (MCP) joints. For the past 30 years, SMPA has been performed on such patients to correct metacarpophalangeal joint deformity in the rheumatoid hand. SMPA can provide pain relief, restoration of function, and aesthetic improvement to the patient. However, because data are limited on its efficacy, SMPA remains a controversial procedure. Hand surgeons and rheumatologists frequently disagree about the indications for this procedure and its value to their patients. In addition, most published studies have been hampered by inadequate consideration of research design, small sample size, and inconsistent outcome measures. The purpose of this study is to measure short- and long-term outcomes following SMPA. The study will also define indications of the surgery for specific patient groups and disease severity. The experiences of both surgery and rheumatology services will be used to jointly evaluate this surgical procedure.
This study is a multicenter, international outcomes study to evaluate RA patients with severe MCP joint problems. Patients will choose to be enrolled into a surgical group undergoing SMPA or a nonsurgical group. Patients will be evaluated at Month 6 and annually until the third year. Patient evaluations will be based on the Michigan Hand Outcomes Questionnaire, the Arthritis Impact Measurement Scales questionnaire, and standard, objective hand function tests.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||170 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||An Outcome Study of Rheumatoid Hand Arthroplasty|
|Study Start Date :||September 2003|
|Actual Primary Completion Date :||August 2017|
|Actual Study Completion Date :||August 2017|
Surgical group undergoing SMPA
Procedure: Silicone metacarpophalangeal joint arthroplasty
Intervention involves reconstructing the metacarpophalangeal joint using the Swanson silastic implant.
Other Name: Swanson silastic implant
Active Comparator: 2
Other: Usual care
Non-surgical usual care
- Michigan Hand Outcomes Questionnaire [ Time Frame: Baseline, 6 months, 1 year, 2 years, 3 year ]
- Arthritis Impact Measurement Scales Questionnaire [ Time Frame: Baseline, 6 months, 1 year, 2 years, 3 years ]
- Standard, objective hand function tests [ Time Frame: Baseline, 6 months, 1 year, 2 years, 3 years ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00124254
|United States, Maryland|
|Curtis National Hand Center|
|Baltimore, Maryland, United States, 21218|
|United States, Michigan|
|University of Michigan|
|Ann Arbor, Michigan, United States, 48109-0340|
|Pulvertaft Hand Centre|
|Derby, United Kingdom|
|Principal Investigator:||Kevin C. Chung, MD, MS||University of Michigan|